DEFA14A: Avidity Adjourns Meeting, Confirms Novartis Merger Dates

Avidity Biosciences has adjourned its Special Stockholder Meeting to February 26, 2026, to finalize conditions for its SpinCo distribution, a prerequisite for the expected February 27, 2026 merger closing with Novartis.

Summary

• Avidity Biosciences, Inc. has adjourned its Special Meeting of Stockholders, originally scheduled for February 23, 2026, at 10:00 a.m. Eastern time.
• The meeting will reconvene virtually on February 26, 2026, at 10:00 a.m. Eastern time.
• The adjournment is to provide additional time to satisfy conditions for the pro rata distribution of all issued and outstanding shares of Atrium Therapeutics, Inc. (SpinCo) common stock to Avidity's stockholders.
• This Distribution is a necessary condition for the closing of Avidity's previously announced merger with Novartis AG.
• The Distribution is now expected to occur on February 26, 2026.
• The closing of the Merger with Novartis is expected to occur on February 27, 2026.
• Both the Distribution and Merger remain subject to respective closing conditions, including stockholder approval.
• Avidity's common stock will temporarily trade on the Nasdaq Global Market under the symbol RNAM beginning on the Distribution date.
• The record date for the Special Meeting remains January 29, 2026.
• Proxies previously submitted will be voted at the reconvened meeting unless revoked.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively as it confirms the expected timeline for the significant merger with Novartis, despite a minor procedural adjournment of the stockholder meeting. The clarity on the Distribution and Merger closing dates reduces uncertainty for investors.

Positives

• The merger with Novartis AG is progressing with expected closing dates now provided.
• The Distribution of SpinCo shares, a key condition for the merger, has an expected date of February 26, 2026.
• The merger closing with Novartis is expected shortly thereafter on February 27, 2026, indicating the transaction is nearing completion.

Negatives

• The Special Meeting of Stockholders was adjourned, requiring a delay in formal stockholder approval.

Risks

• Conditions to the closing of the Transactions (Distribution and Merger) may not be satisfied on the expected timetable or at all.
• The expected benefits or synergies from the Transactions may not be achieved in the expected timeframe, or at all.
• Risks and costs related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation if implemented.
• The risk that competing offers or acquisition proposals will be made.
• The effects of disruption from the Transactions and the impact of the announcement and pendency of the Transactions on Novartis and/or Avidity's businesses, including their relationships with employees, business partners, or governmental entities.
• The risk that the Transactions may be more expensive to complete than anticipated.
• The risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification and liability.
• A diversion of management's attention from ongoing business operations and opportunities as a result of the Transactions or otherwise.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.

Future Outlook

The company expects the distribution of Atrium Therapeutics, Inc. (SpinCo) common stock to occur on February 26, 2026, and the merger with Novartis AG to close on February 27, 2026. These events are contingent upon satisfying all closing conditions, including stockholder approval.

Management Comments

• Avidity intends to convene the Special Meeting and then immediately adjourn proceedings, without conducting any other business.
• Avidity intends to adjourn the Special Meeting to provide additional time to satisfy the conditions to the Distribution.
• The Distribution is expected to occur on February 26, 2026, and the closing of the Merger is expected to occur on February 27, 2026.
• The completion of the Distribution and the Merger each remain subject to the respective closing conditions noted in the Definitive Proxy Statement, including receipt of stockholder approval.
• Stockholders who have previously submitted their proxy or otherwise voted need not take any action. For stockholders who have not yet cast their votes, Avidity encourages them to vote their shares now.

Industry Context

StockSavvy.ai notes that the progression of Avidity's merger with Novartis, a major pharmaceutical company, highlights the continued trend of larger players acquiring innovative biotech firms, particularly those with promising platforms like Avidity's Antibody Oligonucleotide Conjugates (AOCs). This transaction, despite a minor procedural delay in the stockholder meeting, reinforces the strategic value placed on advanced RNA therapeutics and rare disease pipelines within the biopharmaceutical sector. The temporary change in stock symbol (RNAM) is a standard procedural step in such complex transactions, ensuring a smooth transition for investors.

Corporate Governance

Legal Proceedings

• The forward-looking statements section mentions a risk that "stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification and liability," but no active legal proceedings are disclosed in this specific filing.

Stakeholder Impact

• Shareholders: Will receive shares of SpinCo and will be impacted by the merger with Novartis. Those who have not yet voted are encouraged to do so.
• Employees: Potential impacts from the merger with Novartis, though not explicitly detailed in this filing.
• Business Partners: Potential impacts from the merger with Novartis, though not explicitly detailed in this filing.

Next Steps

• Reconvened Special Meeting of Stockholders on February 26, 2026, for stockholder approval.
• Expected pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) common stock on February 26, 2026.
• Expected closing of the Merger with Novartis AG on February 27, 2026.
• Avidity's common stock will temporarily trade under the symbol RNAM on the Nasdaq Global Market starting on the Distribution date.

Key Dates

Recommendation

The filing confirms the progression of a significant merger with Novartis, providing specific expected dates for the Distribution and Merger closing. While the Special Meeting was adjourned, this appears to be a procedural step to ensure all conditions are met, rather than a fundamental issue with the transaction. Given the advanced stage of the merger, a 'hold' recommendation is appropriate for existing shareholders awaiting the completion of the transaction, as the primary value driver is the merger itself, and new investors would need to evaluate the post-merger entity or the terms of the acquisition.

Keywords

Avidity Biosciences, Novartis, Merger, Acquisition, Proxy Statement, Special Meeting, Stockholder Approval, Distribution, Spin-Off, RNA Therapeutics, AOCs, Biopharmaceutical, Nasdaq